Tumor Sidedness Could be a Prognostic Factor in Patients with Stage II Colon Cancer

CURRENT STATUS: UNDER REVIEW

Preprint: Please note that this article has not completed peer review.
Abstract
Background: The search for high-risk factors in stage II colon cancer (CC) is ongoing and several high-risk factors for stage II CC have been identified; however, the effects of tumor sidedness on prognosis is not clear. This study aims to determine whether tumor sidedness could be identified as another high-risk factor for stage II CC.

Methods: We retrospectively analyzed 189 patients with stage II CC, following consecutive curative resection surgery performed between 2008 and 2014. We compared clinicopathological findings and long-term outcomes between the patients with right colonic cancer (RCC) and patients with left colonic cancer (LCC). Prognostic factors for survival were determined using univariate and Cox proportional regression analyses.

Results: A total of 72 patients were diagnosed with RCC and 117 patients were diagnosed with LCC. Patients with RCC were significantly older (p < 0.001) than those with LCC, and the number of harvested lymph nodes (HLNs) was greater in the RCC group (RCC: 25 vs. LCC: 19; p = 0.003). The overall survival (OS) was notably worse in the RCC group than the OS in the LCC group (5 year survival rate—RCC: 81.3% vs. LCC: 90.4%; p = 0.025), whereas no significant difference was observed in disease-free survival (5 year survival rate—RCC: 74.8% vs. LCC: 83.4%; p = 0.065). Cox proportional regression analysis showed that tumor sidedness (hazard ratio (HR): 3.78, 95% confidence interval (CI): 1.61–8.85, p = 0.022), gender (HR: 3.27, 95% CI: 1.27–8.47, p = 0.014), and the number of HLNs (HR: 4.58, 95% CI: 1.95–10.74, p < 0.001) were independent prognostic factors for OS.

Conclusion: Patients with a right-sided primary tumor location have more negative prognostic factors and worse long-term outcomes than those with a left-sided primary tumor location in stage II CC.

Background
Colorectal cancer (CRC) is a major health problem worldwide. CRC is the third most common cancer in the world and the second highest cause of cancer-related death[1, 2]. Recently, several molecular and genetic mechanisms of CRC carcinogenesis have been identified[3, 4]. It has also been reported that the oncological features differ between colon cancer (CC) and rectal cancer[5]. In stage II CC,
there are several high-risk factors, according to the guidelines of the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the Japanese Society for Cancer of the Colon and Rectum (JSCCR)[6-8]. These include bowel obstruction, perforation, poorly differentiated histology, lymphovascular invasion, perineural invasion, pT4, low number of harvested lymph nodes (HLNs; <12), and unclear resection margins. However, these risk factors vary by region, and there is still no rigorous evidence. The search for other prognostic factors in stage II CC is ongoing. For decades, carcinogenetic differences between right colonic cancer (RCC) and left colonic cancer (LCC) have been suggested[9, 10]. Also, there have been reports of differences in clinical, pathological, molecular, and biological features, according to the tumor sidedness, and there has been much debate about the impact of tumor location on prognosis[9, 11, 12]. Nevertheless, few reports have evaluated tumor sidedness as a risk factor of stage II CC, because many of these reports target advanced stage cancers, including metastatic CRC, to analyze the differences in chemotherapy effects. In these advanced stage and metastatic CRCs, molecular and biological differences are considered when selecting a chemotherapy regimen[13, 14]. Meanwhile, investigations into the effects of adjuvant chemotherapy on stage II CRC have not yet been concluded; the main problem being that the high-risk factors have not been identified. Therefore, the current challenges are to identify the high-risk factors and evaluate the benefits of adjuvant chemotherapy. Previous studies of adjuvant chemotherapy for stage II CRC were designed to identify survival benefits, with the focus mainly on high-risk patients[15, 16]. The problem, however, is that most of the previous studies of stage II CRC have not evaluated tumor sidedness. In this study, we hypothesize that differences in tumor sidedness define the prognosis of stage II CC. This study aims to determine the influence of tumor sidedness on the long-term outcomes and prognosis for stage II CC.

Method

Patients

Subjects for the study were selected from patients with CRC at the Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, between January 2008 and December 2014. The inclusion criteria were as follows: (1) patients with stage II colonic adenocarcinoma without rectal cancer, based on the
Union for International Cancer Control’s (UICC) TNM classification (seventh edition); (2) patients had undergone surgery with R0 resection; and (3) patients without synchronous or metachronous malignancy. The selected patients were divided into two groups, based on tumor location (the RCC and LCC groups). RCC was defined as a tumor arising from the cecum, ascending colon, or transverse colon. LCC was defined as a tumor arising from the descending colon, sigmoid colon, or recto-sigmoid colon.

**Surgical procedure and follow-up**

The procedures were performed by colorectal surgeons (with the patients under general anesthesia) and involved a complete mesocolic excision. The method of surgical approach (open surgery or laparoscopic surgery) was determined in each case, depending on the patient's medical history and tumor progression. Laparoscopic surgery was performed using five trocars. Adequate resection margins were determined according to JSCCR guidelines, and D2 or D3 lymphadenectomies were performed in all cases[8]. All patients were followed up regularly at our institution, including carcinoembryonic acid (CEA) and cancer antigen 19 – 9 assays every 3 to 6 months, and computed tomography every 6 to 12 months. A colonoscopy was performed annually, for at least 5 years.

Adjuvant chemotherapy was offered to all high-risk stage II patients having at least one high-risk factor, according to the JSCCR Guidelines for the Treatment of Colorectal Cancer. Treatment was started after pathological evaluation of the tumor specimen, which was performed within 8 weeks of surgery, under informed consent. In adjuvant chemotherapy, oral 5-fluorouracil prodrug (capecitabine) was taken by the patient for 6 months following the operation.

**Evaluation of surgical outcomes and prognostic factors for survival**

We retrospectively compared patient characteristics, including age, gender, and pathological findings, between the RCC group and the LCC group. Tumor histology was described using the World Health Organization classification[17]. Pathological staging was performed according to the UICC’s TNM classification. The surgeries were organized by procedure type, and the data included the extent of lymph node dissection, the number of HLN, duration of surgery, volume of blood loss, postoperative stay, and complications. Postoperative complications were described using the Clavien-Dindo
classification; grade II or higher was considered a major complication in this study[18]. Postoperative results included pathological findings, recurrence rate, overall survival (OS), and disease-free survival (DFS).

Statistical analysis
Statistical analysis included the Student’s t-test, which compares the mean of a continuous variable with a parametric distribution, and the Mann–Whitney U test, for variables with nonparametric distributions. The chi-square test or Fisher’s exact test were used to compare proportions. Survival was estimated by the Kaplan–Meier method, and the group data were compared using the log-rank test. Prognostic factors for survival were determined using univariate and Cox proportional regression analyses. All tests were two-tailed and P-values < 0.05 were considered to be significant.

Results
Demographic and clinicopathological characteristics, and surgical outcomes
A total of 1,398 CRC patients underwent resective surgery at our hospital between January 2008 and December 2014. Of those, 189 patients with stage II CC were extracted, based on the inclusion criteria; 72 were diagnosed with RCC and 117 were diagnosed with LCC. Demographic and clinicopathological characteristics are summarized in Table 1. Patients with RCC were significantly older (p < 0.001) than the LCC patients, and the number of HLNfs was significantly higher in the RCC group (RCC: 25 vs. LCC: 19; p = 0.003). Gender, serum CEA level, tumor diameter, histological type, the incidence of preoperative obstruction and tumor perforation, and the other pathological data did not differ between the two groups. There was no significant difference in the incidence of postoperative complications (Clavien–Dindo classification ≥ II) between the two groups (p = 0.08). A total of 27 patients (14.3%) received adjuvant chemotherapy, and there was no difference in the rate of adjuvant chemotherapy between the two groups (RCC: 12.5% vs. LCC: 19.4%; p = 0.40).
### Table 1
Patients’ characteristics in the RCC and LCC groups

|                          | RCC (n = 72) | LCC (n = 117) | P-value |
|--------------------------|-------------|---------------|---------|
| Age (years) a            | 75 (40–91)  | 71 (44–89)    | < 0.001 |
| Gender                   |             |               |         |
| Male/Female              | 29/43       | 62/55         | 0.10    |
| Tumor location b         |             |               |         |
| C/A/T                    | 13/46/13    | -             | -       |
| D/S/RS                   | -           | 12/71/34      | -       |
| Serum CEA level (ng/ml) a| 3.8 (0.6–260.0) | 4.4 (0.8–87.1) | 0.62    |
| Tumor diameter (mm) a    | 45 (15–130) | 50 (10–150)   | 0.96    |
| Histological type        |             |               |         |
| Differentiated           | 64          | 113           | 0.061   |
| Poorly differentiated    | 8           | 4             |         |
| Obstruction              |             |               |         |
| Yes/No                   | 4/68        | 8/109         | 1.0     |
| Tumor perforation        | 1/71        | 2/115         | 1.0     |
| pT stage                 |             |               |         |
| pT3/pT4                  | 13/59       | 15/102        | 0.40    |
| Lymphovascular invasion  |             |               |         |
| Absent/present           | 15/57       | 38/79         | 0.097   |
| Perineural invasion      |             |               |         |
| Absent/present           | 59/13       | 15/102        | 0.40    |
| Number of harvested a    | 25 (2–53)   | 19 (2–49)     | 0.003   |
| Lymph nodes              |             |               |         |
| Approach                 |             |               |         |
| Open/Laparoscope         | 43/29       | 79/38         | 0.35    |
| Extent of lymphadenectomy|             |               |         |
| D3/D2                    | 57/15       | 87/30         | 0.49    |
| Major complications (C-D classification ≥ II) c | | | |
| Yes/No                   | 23/49       | 23/94         | 0.08    |
| Adjuvant chemotherapy    |             |               |         |
| Yes/No                   | 8/64        | 19/98         | 0.40    |

a median (range)

b C: cecum, A: ascending colon, T: transverse colon, D: descending colon, S: sigmoid colon, RS: rectosigmoid colon
c C-D classification: Clavien-Dindo classification
RCC, right colonic cancer; LCC, left colonic cancer

### Recurrence pattern and post-recurrence therapy between the groups

Recurrence patterns and treatments for recurrence are summarized in Table 2. Ten patients (13.9%) recurred in the RCC group, compared with 14 patients (12.0%) in the LCC group. The recurrence sites were the liver, lungs, peritoneum, and bone. The liver was the most commonly recurring organ in both groups. There was no significant difference between the two groups in recurrence sites (p = 0.44). Treatments for recurrence were performed in 90% and 92.9% of cases in the RCC and LCC groups,
respectively. Five patients (50%) underwent surgery, and four (40%) received chemotherapy in the RCC group. In the LCC group, eight patients (57.2%) underwent surgery, and five (35.7%) received chemotherapy.

Table 2

|                  | RCC (n = 72) | LCC (n = 117) | P-value |
|------------------|-------------|---------------|---------|
| Follow-up period (month) | 59 (9-121)  | 60 (12-122)  | 0.02    |
| Recurrence, n (%)       |             |               |         |
| Total                  | 10 (13.9)   | 14 (12.0)    | 0.82    |
| Recurrence site         |             |               |         |
| Liver                  | 7 (70.0)    | 7 (50.0)     | 0.44    |
| Lung                   | 1 (10.0)    | 5 (35.8)     |         |
| Peritoneal dissemination| 2 (20.0)    | 1 (7.1)      |         |
| Bone                   | 0 (0)       | 1 (7.1)      |         |
| Treatments for recurrence, n (%) |             |               | 1       |
| Surgery                | 5 (50.0)    | 8 (57.2)     |         |
| Chemotherapy           | 4 (40.0)    | 5 (35.7)     |         |
| None                   | 1 (10.0)    | 1 (7.1)      |         |

a median (range)

RCC, right colonic cancer; LCC, left colonic cancer

Long-term outcomes

The survival rates are described in Fig. 1. The OS was significantly lower in the RCC group than in the LCC group (5 year survival rate—RCC: 81.3% vs. LCC: 90.4%; p = 0.025), whereas no significant difference was observed in DFS (5 year survival rate—RCC: 74.8% vs. LCC: 83.4%; p = 0.065).

Prognostic factors for survival of stage II colon cancer

Tables 3 and 4 show the results of the OS and DFS prognostic factor analysis. Univariate analysis revealed that tumor location, gender, histological type, and number of HLN s were prognostic factors for OS, although no significant difference was observed in age, serum CEA level, tumor diameter, obstruction and tumor perforation, pT stage, lymphovascular invasion, perineural invasion, approach, extent of lymphadenectomy, complications, or adjuvant chemotherapy. Cox proportional regression analysis showed that tumor sidedness (hazard ratio (HR): 3.78, 95% confidence interval (CI): 1.61-8.85, p = 0.022), gender (HR: 3.27, 95% CI: 1.27-8.47, p = 0.014), and the number of HLN s (HR: 4.58, 95% CI: 1.95-10.74, p < 0.001) were independent prognostic factors for OS. In univariate analysis for DFS, gender (p = 0.0020) and the number of HLN s (p < 0.001) were prognostic factors, whereas tumor sidedness was not a significant factor (p = 0.065). Multivariate analysis showed that both gender (HR: 2.35, 95% CI: 1.14-4.82, p = 0.020) and the number of HLN s (HR: 2.84, 95% CI: 1.45-5.56, p =
0.0022) were independent prognostic factors for DFS.

### Table 3
Univariate analysis of prognostic factors for stage II colon cancer

| Variables                          | n    | 5 year OS (%) | 5 year DFS (%) | P-value (OS/DFS) |
|------------------------------------|------|---------------|----------------|------------------|
| Age (year)                         |      |               |                |                  |
| <65/≥65                            | 41/148 | 94.5/84.8     | 92.3/76.7      | 0.062/0.057      |
| Gender                             | 91/98 | 80.2/93.3     | 71.3/88.2      | 0.0040/0.0020    |
| Tumor sidedness                    |      |               |                |                  |
| Right/Left                         | 72/117 | 81.3/90.4     | 74.8/83.4      | 0.025/0.065      |
| Serum CEA level (ng/ml)            | <5/≥5 | 89.3/85.5     | 80.9/79.0      | 0.34/0.56        |
| Tumor diameter (mm)                |      |               |                |                  |
| <50/≥50                            | 96/93 | 88.9/85.2     | 82.5/77/9      | 0.62/0.54        |
| Histological type                  |      |               |                |                  |
| Differentiated                     | 177  | 87.9          | 80.5           | 0.037/0.24       |
| Poorly differentiated              | 12   | 75.0          | 75.0           |                  |
| Obstruction                        |      |               |                |                  |
| Yes/No                             | 12/177 | 86.6/91.7     | 75.0/80.5      | 0.84/0.33        |
| Tumor perforation                  |      |               |                |                  |
| Yes/No                             | 3/186 | 66.7/87.3     | 66.7/80.4      | 0.37/0.69        |
| pT stage                           |      |               |                |                  |
| pT3/pT4                            | 161/28 | 87.6/83.7     | 81.9/69.7      | 0.46/0.10        |
| Lymphovascular invasion            |      |               |                |                  |
| Absent/present                     | 53/136 | 89.8/85.8     | 86.1/77.8      | 0.30/0.14        |
| Perineural invasion                |      |               |                |                  |
| Absent/present                     | 161/28 | 85.9/96.2     | 79.9/82.6      | 0.26/0.78        |
| Number of harvested Lymph nodes    |      |               |                |                  |
| <12/≥12                            | 38/151 | 67.3/91.4     | 55.0/86.0      | < 0.001/<0.001   |
| Approach                           |      |               |                |                  |
| Open/Laparoscope                   | 122/67 | 85.3/90.2     | 78.1/84.0      | 0.33/0.30        |
| Extent of lymphadenectomy           |      |               |                |                  |
| D3/D2                              | 144/45 | 88.9/80.9     | 82.2/73/5      | 0.15/0.39        |
| Major complications (C-D classification ≥ II) a |       |               |                |                  |
| Yes/No                             | 46/143 | 80.5/89.0     | 78.8/80.6      | 0.36/0.90        |
| Adjuvant chemotherapy              |       |               |                |                  |
| Yes/No                             | 27/162 | 83.2/87.7     | 73.1/81.3      | 0.84/0.43        |

a C-D classification: Clavien-Dindo classification

OS, overall survival; DFS, disease free survival
Table 4
Multivariate analysis of prognostic factors for stage II colon cancer

| Variables             | Overall survival | Disease free survival |
|-----------------------|------------------|-----------------------|
|                       | Hazard ratio     | 95% confidence interval | P-value | Hazard ratio | 95% confidence interval | P-value |
| Gender                |                  |                       |         | Gender       |                       |         |
| Male vs Female        | 3.27             | 1.27–8.47             | 0.014   | Male vs Female | 2.35              | 1.14–4.82 | 0.020 |
| Tumor sidedness      |                  |                       |         |              |                       |         |
| Right vs Left         | 3.78             | 1.61–8.85             | 0.022   |              |                       |         |
| Histological type     |                  |                       |         |              |                       |         |
| Poorly differentiated vs differentiated | 1.99 | 0.66–5.98 | 0.22 |              |                       |         |
| Number of harvested Lymph nodes | <12 vs ≥ 12 | 4.58 | 1.95–10.74 | < 0.001 | <12 vs ≥ 12 | 2.84 | 1.45–5.56 | 0.0022 |

Discussion

This study investigated the long-term outcomes and prognostic factors for stage II CC, according to the tumor sidedness. It confirmed that tumor sidedness has a major influence on prognosis. The main clinicopathological findings of this study were that stage II RCC was more frequent in more elderly patients and was characterized by a higher number of dissected lymph nodes, when compared with stage II LCC patients. Furthermore, tumor sidedness was an independent prognostic factor for OS, and the number of HLNds and gender were independent factors for both OS and DFS. For decades, there have been many suggestions that tumor location in CC potentially influences prognosis because of clinical and biological differences. Furthermore, it appears that tumors arising in right colonic lesions have different molecular and genetic pathways, when compared with those arising in left colonic lesions[3, 13, 19].

In related studies, it was reported that defective mismatch repair genes, high microsatellite instability (MSI-H), BRAF/KRAS mutations, and CpG island methylator phenotype positive were the notable characteristics of RCC, whereas LCC was characterized by frequent NRAS and p53 mutations[4, 13, 20–22]. These molecular and genetic features of CC that were due to the tumor location have been associated with prognosis, and the treatment, such as 5-fluorouracil-based chemotherapy or anti-
EGFR therapy[19, 23, 24]. Meanwhile, in stage II CC, the efficacy and role of adjuvant chemotherapy is still uncertain[16, 25]. In addition, there is an ongoing debate over which factors are high risk in the prognosis for stage II CC. Although tumor sidedness is not included as a stage II high-risk factor in the current guidelines, attention must be paid to tumor location in view of these molecular biological differences.

Several previous reports have indicated that RCC patients have lower survival rates than those with LCC. For example, Meguid et al. reported the survival analysis of 77,978 colorectal cancer patients, using the Surveillance, Epidemiology, and End Results program database. They found that median survival for RCC was 78 months, compared with 89 months for LCC (p < 0.001), indicating poor prognosis for RCC patients[26]. Mejri et al. also reported the prognostic impact of tumor location for stage II/III CC. Two hundred and three patients with stage II/III CC were analyzed, and it was found that 5 year OS was significantly worse in RCC than in LCC (65% vs. 82%, HR: 2.07; 95% CI: 1.05–4.09; p = 0.03)[27]. A systemic review and meta-analysis of prognostic survival associated with tumor localization was reported in Italy. Petreli et al. analyzed 66 studies, which included 1,437,846 patients, and revealed that LCC patients had a low risk of death, when compared with RCC (HR: 0.82; 95% CI: 0.79–0.84; p < 0.01). This trend was independent of stage, race, adjuvant chemotherapy, and year of study[28]. These findings are compatible with our results.

One notable evaluation factor based on tumor sidedness is the number of HLNs. In stage II CRC, current guidelines suggest that fewer than 12 lymph nodes harvested is considered a high-risk factor[6, 7]. Low lymph node yields may result in positive lymph nodes being missed and increase the risk of under staging[29, 30]. Tsai et al. analyzed 1,167 stage I–III CRC patients and categorized high harvests (≥ 12 lymph nodes) and low harvests (< 12 lymph nodes). They found that patients with low harvests had poorer OS with stages II and III CRC (stage II: p < 0.0001; stage III: p = 0.001)[31]. In the present study, similar results were obtained, and multivariate analysis showed that the number of lymph nodes was a significantly independent factor for both OS and DFS. Furthermore, the number of HLNs was higher in the RCC group than in the LCC group (23.8 vs. 19.2, p = 0.003). Mik et al. also reported that the total number of HLNs was higher in the RCC group (11.7 vs. 8.3; p = 0.0001), and
these results are similar to our own findings[32]. The reason for this was due to the differences in the resected area, depending on the tumor location. The right-sided colon mesentery may anatomically contain a more complex lymphatic system and a larger area of resection, when compared with the left-sided colon[33, 34]. Therefore, the reference value for the number of lymph node dissections may be better considered separately for each tumor location.

In this study, tumor sidedness was not an independent prognostic factor for DFS, although a certain trend was observed (p = 0.065). However, tumor sidedness is an independent factor for OS in stage II CC. We speculate that RCC could have a greater potential for malignancy with poor biological behavior, once it has recurred, when compared with LCC. Therefore, our results strongly indicate that RCC should be considered as a risk factor for stage II CC. In addition, it is necessary to develop multidisciplinary treatment strategies that include tumor sidedness, as well as pathological and genomic factors.

This study has some limitations. First, the small sample size, retrospective design, and single-center setting may limit the generalization of results. Second, this study did not include the status of BRAF/KRAS/NRAS mutations, MSI, sporadic mismatch repair deficiency, germline mutation-prompted Lynch syndrome, or any family history. These genomic and epigenomic characteristics should be considered, in addition to the tumor location. Therefore, it is necessary to conduct randomized controlled trials with a large sample size, including genomic information, at multiple institutions across different countries, to confirm the prognostic factors in stage II CC.

Conclusions
In conclusion, this study revealed that tumor sidedness was an independent prognostic factor for OS in stage II CC. We strongly suggest that tumor sidedness should be considered as a high-risk factor in stage II CC patients, in addition to the traditional factors.

Abbreviations
BRAF: v-raf murine sarcoma viral oncogene homolog B; CC: colon cancer; CI: confidence interval; CEA: carcinoembryonic acid; CRC: colorectal cancer; DFS: disease-free survival; EGFR: epidermal growth factor receptor; HLN: harvested lymph node; HR: Hazard ratio; KRAS: Kirsten rat sarcoma viral
oncogene; LCC: left colonic cancer; MSI-H: high microsatellite instability; NRAS: neuroblastoma ras viral oncogene homolog; OS: overall survival; RCC: right colonic cancer

Declarations

**Ethics approval and consent to participate**

The study was conducted following the ethical guidelines of the Declaration of Helsinki. The protocol of this study was approved by the Ethics Committees of Saiseikai Yokohamashi Nanbu Hospital (Ethical approval number: NANBU-D23).

**Consent for publication**

All authors read and approved the final manuscript.

**Availability of data and materials**

Not applicable.

**Competing interests**

All authors declare no conflict of interest.

**Funding**

Not applicable

**Authors' contributions**

All authors contributed equally to this study. Details of contributions by each author are as follows; Concept and study design were conducted by KI, HM, SH, DI, YM and TF. Data collection and literature search were done by KI, HM, MN. Data analysis and interpretation were done by KI, HM, HT, NY, YR and MM. Interpretation of data was done by investigators. Drafting the article was done by KI and HM. Finally, this article was revised and approved by all investigators.

**Acknowledgements**

The authors would like to give heartfelt thanks to all pathologists at the Saiseikai Yokohamashi Nanbu Hospital who always provided carefully considered feedback and valuable comments.

**Authors' information**

1 Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan

2 Department of Surgery, Yokohama City University, School of Medicine, Yokohama, Japan
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

2. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177-93.

3. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;38:511-20.

4. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010;36:550-6.

5. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst. 2013;105:1806-13.

6. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN Guidelines Insights Colon Cancer, Version 2.2018. J Natl Compr Cancer Netw. 2018;16:359-69.

7. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi64-72.

8. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42.

9. Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - A systematic review. Eur J Surg Oncol. 2015;41:300-8.

10. Yang J, Du XL, Li ST, Wang BY, Wu YY, Chen ZL, et al. Characteristics of differently
located colorectal cancers support proximal and distal classification: A population-based study of 57,847 patients. PLoS One 2016;11:e0167540

11. Wang B, Yang J, Li S, Lv M, Chen Z, Li E, et al. Tumor location as a novel high risk parameter for stage II colorectal cancers. PLoS One 2017;12:e0179910

12. Signorelli C, Chilelli MG, Sperduti I, Giacinti S, Amodio PM, Palmieri RM, et al. Correlation of tumor location to clinical outcomes in colorectal cancer: A Single-institution Retrospective Analysis. Anticancer Res. 2019;39:4917–24.

13. Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21:6470–8.

14. Grassadonia A, Di Marino P, Ficorella C, Cortellini A, Cannita K, Parisi A, et al. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study. J Cancer 2019;10:5926–34.

15. dos Santos LV., Faria TMV, Lima ABC, Abdalla KC, de Moraes ED, Cruz MR, et al. Timing of adjuvant chemotherapy in colorectal cancer. Color Dis. 2016;18:871–6.

16. Jalaeikhoo H, Zokaasadi M, Khajeh-Mehrizi A, Rajaeinejad M, Mousavi SA, Vaezi M, et al. Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study. J Res Med Sci. 2019;24:39.

17. Bosman FT, Carneiro F, Hruban RH, Theise ND. eds. WHO Classification of Tumours of the Digestive System, Fifth Edition. In: International Agency for Research on Cancer. 2019.

18. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. Ann Surg. 2004;240:205–13.

19. Kim SR, Song N, Yothers G, Gavin PG, Allegra CJ, Paik S, et al. Tumour sidedness and
intrinsic subtypes in patients with stage II/III colon cancer: Analysis of NSABP C-07 (NRG Oncology). Br J Cancer 2018;118:629–33.

20. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816–9.

21. Hughes LAE, Khalid-de Bakker CAJ, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochim Biophys Acta. 2012;1825:77–85.

22. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.

23. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

24. George B, Kopetz S. Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep. 2011;13:206–15.

25. Wu X, Zhang J, He X, Wang C, Lian L, Liu H, et al. Postoperative Adjuvant Chemotherapy for Stage II Colorectal Cancer: A Systematic Review of 12 Randomized Controlled Trials. J Gastrointest Surg. 2012;16:646-55.

26. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388-94.

27. Mejri N, Dridi M, El Benna H, Labidi S, Daoud N, Boussen H. Tumor location impact in stage II and III colon cancer: Epidemiological and outcome evaluation. J Gastrointest Oncol. 2018;9:263–8.
28. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211–9.

29. Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, et al. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. J Cancer Res Clin Oncol. 2016;142:2051–9.

30. Märkl B. Stage migration vs immunology: The lymph node count story in colon cancer. World J Gastroenterol. 2015;21:12218–33.

31. Tsai HL, Huang CW, Yeh YS, Ma CJ, Chen CW, Lu CY, et al. Factors affecting number of lymph nodes harvested and the impact of examining a minimum of 12 lymph nodes in stage I-III colorectal cancer patients: A retrospective single institution cohort study of 1167 consecutive patients. BMC Surg. 2016;16:17.

32. Mik M, Berut M, Dziki L, Trzcinski R, Dziki A. Right-and left-sided colon cancer—clinical and pathological differences of the disease entity in one organ. Arch. Med Sci. 2017;13:157–62.

33. Yang L, Xiong Z, Xie Q, He W, Liu S, Kong P, et al. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer. 2018;18:558.

34. Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum. 2008;51:154–61.

Figures
Overall survival and disease-free survival of stage II colon cancer compared with tumor sidedness. The Kaplan–Meier analysis of overall survival and disease-free survival by tumor sidedness. The OS was significantly lower in the RCC group than in the LCC group (5 year survival rate—RCC: 81.3% vs. LCC: 90.4%; p = 0.025), whereas no significant difference was observed in DFS (5 year survival rate—RCC: 74.8% vs. LCC: 83.4%; p = 0.065).